Navigation Links
Relmada Therapeutics Inc. Completes $8.0 Million Capital Raise In Series A Financing

NEW YORK, Oct. 1, 2013 /PRNewswire/ -- Relmada Therapeutics Inc., a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced the final closing of a Series A financing raising $8 million in gross proceeds.  The offer was oversubscribed and Laidlaw & Company (UK) Ltd. acted as the exclusive placement agent.   

The company intends to use the Series A proceeds to continue the development of its product pipeline and for general corporate activities.  "This impressive response from investors clearly shows the potential of our diversified product portfolio of drug candidates aimed to address the significant unmet medical need in chronic pain," said Sergio Traversa, CEO of Relmada.  Based on this successful offering, we plan to complete the required steps for LevoCap ER to enter Phase III of development, d-methadone to enter Phase IIb, MepiGel and BuCap to start the pilot PK studies and to prepare the company for a public transaction in the first half of 2014.

About Relmada Therapeutics

Relmada Therapeutics, Inc. is a clinical stage, private biopharmaceutical company with a diversified portfolio of four products and a deep early stage pipeline for the treatment of pain.  Relmada's strategy focuses on two complementary pillars: the improvement of proven drug candidates with novel delivery methods and pharmaceutical compositions and the development of d-methadone as an innovative NMDA (N-Methyl-D-aspartate) inhibitor platform. 

The Company is currently developing several drug candidates including: LevoCap ER, its abuse resistant, once–a-day sustained release dosage form of the opioid analgesic levorphanol; d-methadone, the NDMA receptor antagonist for diabetic painful neuropathy (DPN); BuCap, its oral dosage form of the opioid analgesic buprenorphine; MepiGel, its FDA Orphan Drug designated topical formulation of the local anesthetic mepivacaine.

About Laidlaw & Company, LTD.

Laidlaw & Company is a full service investment bank and securities brokerage firm with offices in New York, London, San Francisco and select additional locations.  Its corporate finance efforts are focused on the healthcare, natural resource and social commerce sectors.  In addition to capital raising, its investment banking arm provides M&A, restructuring and other financial advisory services for public and private small cap and middle market clients across a broad cross‐section of industry sectors.  Its brokerage arm provides wealth management services for domestic and international high‐net‐worth and institutional clients.  Laidlaw is authorized by the FSA in the United Kingdom, and is regulated by FINRA in the United States. (Source:

Safe Harbor Statement

This release contains forward‐looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein that do not describe historical facts are forward‐looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward looking statements. The Company assumes no obligation to update or supplement any forward‐looking statements whether as a result of new information, future events or otherwise.

Visit our website at

SOURCE Relmada Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Relmada Therapeutics Raises $3.0 Million In Initial Closing Of Series A Financing
2. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
3. Nile Therapeutics Reports 2011 Third Quarter Financial Results
4. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
5. Fate Therapeutics Strengthens Its iPSC Platform
6. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
7. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
8. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
9. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
10. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
11. Aratana Therapeutics Completes $15 Million Series B Financing
Post Your Comments:
(Date:11/24/2015)... Malaysia , Nov. 24, 2015  Asia-Pacific ... contract research organisation (CRO) market. The trend of ... in lower margins but higher volume share for ... capacity and scale, however, margins in the CRO ... Organisation (CRO) Market ( ), finds ...
(Date:11/24/2015)... ... November 24, 2015 , ... Copper is an essential ... bound to proteins, copper is also toxic to cells. With a $1.3 million ... (WPI) will conduct a systematic study of copper in the bacteria Pseudomonas aeruginosa ...
(Date:11/24/2015)... PHILADELPIA, PA (PRWEB) , ... November 24, 2015 , ... ... young entrepreneurs at competitive events in five states to develop and pitch their BIG ... student projects from each state are competing for votes to win the title of ...
(Date:11/24/2015)... QUEBEC CITY , Nov. 24, 2015 /PRNewswire/ ... (the "Company") announced today that the remaining 11,000 ... Common Share Purchase Warrants (the "Series B Warrants") ... agreement were exercised on November 23, 2015, which ... Common Shares.  After giving effect to the issuance ...
Breaking Biology Technology:
(Date:11/17/2015)... Paris from 17 th until 19 th ... from 17 th until 19 th November 2015.   ... the first combined scanner in the world which scans both ... two different scanners were required: one for passports and one ... same surface. This innovation is an ideal solution for electronic ...
(Date:11/12/2015)... Nov. 12, 2015  A golden retriever that stayed ... dystrophy (DMD) has provided a new lead for treating ... the Broad Institute of MIT and Harvard and the ... . Cell, pinpoints a protective ... the disease,s effects. The Boston Children,s lab of ...
(Date:11/10/2015)... 2015 About signature verification ... to identify and verify the identity of an ... the secure and accurate method of authentication and ... individual because each individual,s signature is highly unique. ... dynamic signature of an individual is compared and ...
Breaking Biology News(10 mins):